Meta-analysis of the CYP1A2 -163C>A Polymorphism and Lung Cancer Risk

  • Deng, Sheng-Qiong (Department of Preventive Medicine, Institute of Basic Medical Sciences, Hubei University of Medicine) ;
  • Zeng, Xian-Tao (Department of Stomatology, Taihe Hospital, Hubei University of Medicine) ;
  • Wang, Yun (Department of Respiratory Medicine, Taihe Hospital, Hubei University of Medicine) ;
  • Ke, Qing (Department of Oncology, Taihe Hospital, Hubei University of Medicine) ;
  • Xu, Qiong-Li (Department of Stomatology, Taihe Hospital, Hubei University of Medicine)
  • Published : 2013.05.30


Many published studies have concerned associations between the CYP1A2 -163 C>A polymorphism and risk of lung cancer, but the results have been inconsistent. Therefore, we performed a meta-analysis to obtain a more precise estimate. We searched the PubMed database up to March 1, 2013 for relevant cohort and case-control studies. Supplementary search was conducted manually by searching the references of the included studies and relevant meta-analyses. A meta-analysis was performed using RevMan 5.2 software for calculation of pooled odds ratios (ORs) and relevant 95% confidence intervals (CIs) after data extraction. Finally, seven case-control studies and one nested case-control study involving 1,675 lung cancer patients and 2,393 controls were included. The meta-analysis showed that there was no association of CYP1A2 -163 C>A polymorphism with risk of lung cancer overall [(OR=0.89, 95%CI= 0.74-1.07) for C vs. A; (OR=0.73, 95%CI= 0.50-1.07) for AA vs. CC ; (OR=0.82, 95%CI= 0.62-1.09) for AC vs. CC; (OR=0.79, 95%CI= 0.58-1.07) for (AC+AA) vs. CC; and (OR=0.87, 95%CI= 0.67-1.13) for AA vs. (CC+AC)]. Subgroup analysis indicated that there was an associationbetween CYP1A2 -163C>A polymorphism and lung cancer risk for population-based controls, a trend risk for SCCL (squamous cell carcinoma of lung) and Caucasians. These results suggested that -163 C>A polymorphism is likely to be associated with risk of lung cancer compared with population-based controls.


  1. Aldrich MC, Selvin S, Hansen HM, et al (2009). CYP1A1/2 haplotypes and lung cancer and assessment of confounding by population stratification. Cancer Res, 69, 2340-48.
  2. B'Chir F, Pavanello S, Knani J, et al (2009). CYP1A2 genetic polymorphisms and adenocarcinoma lung cancer risk in the Tunisian population. Life Sci, 84, 779-84.
  3. Boobis AR, Lynch AM, Murray S, et al (1994). CYP1A2-catalyzed conversion of dietary heterocyclic amines to their proximate carcinogens is their major route of metabolism in humans. Cancer Res, 54, 89-94.
  4. Gemignani F, Landi S, Szeszenia-Dabrowska N, et al (2007). Development of lung cancer before the age of 50, the role of xenobiotic metabolizing genes. Carcinogenesis, 28, 1287-93.
  5. Gervasini G, Ghotbi R, Aklillu E, et al (2013). Haplotypes in the 5'-untranslated region of the CYP1A2 gene are inversely associated with lung cancer risk but do not correlate with caffeine metabolism. Environ Mol Mutagen, 54, 124-32.
  6. Huedo-Medina TB, Sanchez-Meca J, Marin-Martinez F, et al (2006). Assessing heterogeneity in meta-analysis, Q statistic or I2 index? Psychol Methods, 11, 193-206.
  7. Jin JQ, Hu YY, Niu YM, et al (2011). CYP1A1 Ile462Val polymorphism contributes to colorectal cancer risk, a metaanalysis. World J Gastroenterol, 17, 260-6.
  8. Leng WD, Zeng XT, Chen YJ, et al (2012). Cytochrome P450 2E1 RsaI/PstI polymorphism and risk of esophageal cancer, A meta-analysis of 17 case-control studies. Exp Ther Med, 4, 938-48.
  9. Lohmueller KE, Pearce CL, Pike M, et al (2003). Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease. Nat Genet, 33, 177-82.
  10. Munafo MR, Flint J (2004). Meta-analysis of genetic association studies. Trends Genet, 20, 439-44.
  11. Niu Y, Hu Y, Wu M, et al (2012). CYP2E1 Rsa I/Pst I polymorphism contributes to oral cancer susceptibility, a meta-analysis. Mol Biol Rep, 39, 607-12.
  12. Osawa Y, Osawa KK, Miyaishi A, et al (2007). NAT2 and CYP1A2 polymorphisms and lung cancer risk in relation to smoking status. Asian Pac J Cancer Prev, 8, 103-8.
  13. Pavanello S, Fedeli U, Mastrangelo G, et al (2012). Role of CYP1A2 polymorphisms on lung cancer risk in a prospective study. Cancer Genet, 205, 278-84.
  14. Sachse C, Brockmoller J, Bauer S, et al (1999). Functional significance of a C-->A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol, 47, 445-9.
  15. Singh AP, Pant MC, Ruwali M, et al (2010). Polymorphism in cytochrome P450 1A2 and their interaction with risk factors in determining risk of squamous cell lung carcinoma in men. Cancer Biomark, 8, 351-9.
  16. Wang H, Zhang Z, Han S, et al (2012). CYP1A2 rs762551 polymorphism contributes to cancer susceptibility, a metaanalysis from 19 case-control studies. BMC Cancer, 12, 528.
  17. Zhou SF, Chan E, Zhou ZW, et al (2009). Insights into the structure, function, and regulation of human cytochrome P450 1A2. Curr Drug Metab, 10, 713-29.
  18. Zienolddiny S, Campa D, Lind H, et al (2008). A comprehensive analysis of phase I and phase II metabolism gene polymorphisms and risk of non-small cell lung cancer in smokers. Carcinogenesis, 29, 1164-9.

Cited by

  1. Four Polymorphisms in the Cytochrome P450 1A2 (CYP1A2) Gene and Lung Cancer Risk: a Meta-analysis vol.15, pp.14, 2014,
  2. Lack of association between polymorphisms in the CYP1A2 gene and risk of cancer: evidence from meta-analyses vol.16, pp.1, 2016,